PharmaShots | Incisive News in 3 Shots

Subscribe Now

SAB Biotherapeutics

SAB Biotherapeutics’ SAB-176 Receives US FDA’s Fast Track Designation for the Treatment of Type A and Type B Influenza

SAB Biotherapeutics’ SAB-176 Receives US FDA’s Fast Track Designation for the Treatment of Type A and Type B Influenza

April 14, 2023

SAB Biotherapeutics Discontinues P-III (ACTIV-2) Trial of SAB-185 for the Treatment of COVID-19

SAB Biotherapeutics Discontinues P-III (ACTIV-2) Trial of SAB-185 for the Treatment of COVID-19

March 3, 2022

Top COVID-19 Deals (Part III): Biopharma and Govt. Institutions

Top COVID-19 Deals (Part III): Biopharma and Govt. Institutions

June 26, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us